Breast Cancer Clinical Trials in San Diego

Showing 121-140 of 400 trials

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

NCT01766297

The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to compare the results (good or bad) of proton radiation therapy.

Breast CancerBreast NeoplasmBreast Tumor+1 more

Proton Collaborative Group132 participantsStarted Feb 2013

Scottsdale, Arizona, United States • San Diego, California, United States • Warrenville, Illinois, United States +6 more locations

Active Not RecruitingPhase 3< 1 mile

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

NCT04379570

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+6 more

Alliance for Clinical Trials in Oncology1,167 participantsStarted Feb 2021

Birmingham, Alabama, United States • Fairbanks, Alaska, United States • Gilbert, Arizona, United States +523 more locations

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Breast Cancer Trials in Other Cities

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

A Study of ADRX-0706 in Select Advanced Solid Tumors

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

MarginProbe 2.0 Data Collection Protocol

MGC018 With or Without MGA012 in Advanced Solid Tumors

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Other Conditions in San Diego